A Phase I, First-in-human, Randomized, Observer-blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV601 in Healthy Adult Volunteers
Latest Information Update: 24 Jan 2023
At a glance
- Drugs BV 601 (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; First in man
- Sponsors BravoVax
- 09 Jan 2023 New trial record